Steven D. Knight

2.1k total citations
29 papers, 610 citations indexed

About

Steven D. Knight is a scholar working on Molecular Biology, Organic Chemistry and Surgery. According to data from OpenAlex, Steven D. Knight has authored 29 papers receiving a total of 610 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Organic Chemistry and 3 papers in Surgery. Recurrent topics in Steven D. Knight's work include Epigenetics and DNA Methylation (4 papers), Chemical synthesis and alkaloids (4 papers) and Chemical Synthesis and Analysis (3 papers). Steven D. Knight is often cited by papers focused on Epigenetics and DNA Methylation (4 papers), Chemical synthesis and alkaloids (4 papers) and Chemical Synthesis and Analysis (3 papers). Steven D. Knight collaborates with scholars based in United States, United Kingdom and Poland. Steven D. Knight's co-authors include Larry E. Overman, Garry Pairaudeau, Cynthia A. Parrish, Dashyant Dhanak, Robert W. Marquis, Steven R. Angle, John M. Fevig, Stephen A. Douglas, David J. Behm and Eliot H. Ohlstein and has published in prestigious journals such as Journal of the American Chemical Society, The Journal of Experimental Medicine and British Journal of Pharmacology.

In The Last Decade

Steven D. Knight

27 papers receiving 582 citations

Peers

Steven D. Knight
Olivier Duclos France
Jorge Gomez‐Galeno United States
Toshihiro Kiho Japan
Stephen E. de Laszlo United States
Sultan Nacak Baytaş Türkiye
Roger P. Dickinson United Kingdom
Hea-Young Park Choo South Korea
Fujio Tabusa Japan
Sarah J. Fink United States
M. Jonathan Fray United Kingdom
Olivier Duclos France
Steven D. Knight
Citations per year, relative to Steven D. Knight Steven D. Knight (= 1×) peers Olivier Duclos

Countries citing papers authored by Steven D. Knight

Since Specialization
Citations

This map shows the geographic impact of Steven D. Knight's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven D. Knight with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven D. Knight more than expected).

Fields of papers citing papers by Steven D. Knight

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven D. Knight. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven D. Knight. The network helps show where Steven D. Knight may publish in the future.

Co-authorship network of co-authors of Steven D. Knight

This figure shows the co-authorship network connecting the top 25 collaborators of Steven D. Knight. A scholar is included among the top collaborators of Steven D. Knight based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven D. Knight. Steven D. Knight is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tian, Xinrong, K. A. NEWLANDER, Louis V. LaFrance, et al.. (2025). Asymmetric synthesis of potent and orally bioavailable thiophene-based EZH2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 127. 130291–130291. 1 indexed citations
2.
Wetherall, David, Abdul Kabbani, Van Jacobson, et al.. (2023). Improving Network Availability with Protective ReRoute. 684–695. 3 indexed citations
3.
Yang, Tianrui, et al.. (2021). A review of alternative intravenous acetylcysteine regimens for acetaminophen overdose. Expert Review of Clinical Pharmacology. 14(10). 1267–1278. 3 indexed citations
4.
Shreffler, Jacob, et al.. (2020). Opioid Overdoses for Recently Incarcerated Individuals: Toxicology Results and Risk Evaluations. Substance Use & Misuse. 55(8). 1356–1360.
5.
Dobenecker, Marc‐Werner, Joon Seok Park, Michael T. McCabe, et al.. (2018). Signaling function of PRC2 is essential for TCR-driven T cell responses. The Journal of Experimental Medicine. 215(4). 1101–1113. 38 indexed citations
6.
Knight, Steven D., et al.. (2016). Medical Mimics of Psychiatric Conditions, Part 2. 48(6). 258–265. 2 indexed citations
7.
Ott, Heidi M., Alan P. Graves, Melissa B. Pappalardi, et al.. (2014). A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation. Molecular Cancer Therapeutics. 13(12). 3062–3073. 35 indexed citations
8.
Knight, Steven D. & Cynthia A. Parrish. (2008). Recent Progress in the Identification and Clinical Evaluation of Inhibitors of the Mitotic Kinesin KSP. Current Topics in Medicinal Chemistry. 8(10). 888–904. 46 indexed citations
9.
Jin, Jian, Ming An, Anthony Sapienza, et al.. (2008). Urotensin-II receptor antagonists: Synthesis and SAR of N-cyclic azaalkyl benzamides. Bioorganic & Medicinal Chemistry Letters. 18(14). 3950–3954. 14 indexed citations
10.
Adams, Nicholas D., Stanley J. Schmidt, Steven D. Knight, & Dashyant Dhanak. (2007). A novel synthesis of substituted 4H-pyrazolo[3,4-d]pyrimidin-4-ones. Tetrahedron Letters. 48(23). 3983–3986. 5 indexed citations
11.
Sutton, David, Aidan G. Gilmartin, Chiu-Mei Sung, et al.. (2007). A potent and selective inhibitor of the mitotic kinesin CENP-E (GSK923295A), demonstrates a novel mechanism of inhibiting tumor cell proliferation and shows activity against a broad panel of human tumor cell lines in vitro. 6. 5 indexed citations
12.
Jackson, Jeffrey R., Aidan G. Gilmartin, Steven D. Knight, et al.. (2006). A second generation KSP inhibitor, SB-743921, is a highly potent and active therapeutic in preclinical models of cancer. 12. 11 indexed citations
13.
Jin, Jian, Dashyant Dhanak, Steven D. Knight, et al.. (2005). Aminoalkoxybenzyl pyrrolidines as novel human urotensin-II receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 15(13). 3229–3232. 17 indexed citations
14.
Behm, David J., Christopher L. Herold, Eliot H. Ohlstein, et al.. (2002). Pharmacological characterization of SB‐710411 (Cpa‐c[D‐Cys‐Pal‐D‐Trp‐Lys‐Val‐Cys]‐Cpa‐amide), a novel peptidic urotensin‐II receptor antagonist. British Journal of Pharmacology. 137(4). 449–458. 42 indexed citations
15.
Dhanak, Dashyant, Michael G. Darcy, Richard M. Keenan, et al.. (2001). Discovery of potent and selective phenylalanine derived CCR3 receptor antagonists. Part 2. Bioorganic & Medicinal Chemistry Letters. 11(11). 1445–1450. 23 indexed citations
16.
Knight, Steven D., et al.. (1999). RCN (Royal College of Nursing) A&E Nursing Association. Adolescent's in A&E. A position statement.. PubMed. 7(3). 6–7. 3 indexed citations
17.
Smith, Amos B., Steven D. Knight, Paul A. Sprengeler, & Ralph Hirschmann. (1996). The design and synthesis of 2,5-linked pyrrolinones. A potential non-peptide peptidomimetic scaffold. Bioorganic & Medicinal Chemistry. 4(7). 1021–1034. 21 indexed citations
18.
Knight, Steven D., Ricardo Miledi, Nguyêñ Quôć Thǎńg, Larry E. Overman, & Garry Pairaudeau. (1995). The enantiomer of strychnine is a weak antagonist of the inhibitory glycine receptor. Bioorganic & Medicinal Chemistry Letters. 5(7). 749–752. 4 indexed citations
19.
Knight, Steven D., Larry E. Overman, & Garry Pairaudeau. (1995). Asymmetric Total Syntheses of (-)- and (+)-Strychnine and the Wieland-Gumlich Aldehyde. Journal of the American Chemical Society. 117(21). 5776–5788. 103 indexed citations
20.
Angle, Steven R., John M. Fevig, Steven D. Knight, Robert W. Marquis, & Larry E. Overman. (1993). Synthesis applications of cationic aza-Cope rearrangements. 24. The aza-Cope-Mannich approach to Strychnos alkaloids. Short stereocontrolled total syntheses of (.+-.)-dehydrotubifoline and (.+-.)-akuammicine. Journal of the American Chemical Society. 115(10). 3966–3976. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Olivier Duclos Breakdown of academic impact, for papers by Jorge Gomez‐Galeno Breakdown of academic impact, for papers by Toshihiro Kiho Breakdown of academic impact, for papers by Stephen E. de Laszlo Breakdown of academic impact, for papers by Sultan Nacak Baytaş Breakdown of academic impact, for papers by Roger P. Dickinson Breakdown of academic impact, for papers by Hea-Young Park Choo Breakdown of academic impact, for papers by Fujio Tabusa Breakdown of academic impact, for papers by Sarah J. Fink Breakdown of academic impact, for papers by M. Jonathan Fray
Rankless by CCL
2026